These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27158367)

  • 1. Systemic delivery to central nervous system by engineered PLGA nanoparticles.
    Cai Q; Wang L; Deng G; Liu J; Chen Q; Chen Z
    Am J Transl Res; 2016; 8(2):749-64. PubMed ID: 27158367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Elvitegravir Nanoformulation Crosses the Blood-Brain Barrier and Suppresses HIV-1 Replication in Microglia.
    Gong Y; Zhi K; Nagesh PKB; Sinha N; Chowdhury P; Chen H; Gorantla S; Yallapu MM; Kumar S
    Viruses; 2020 May; 12(5):. PubMed ID: 32443728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functionalized PLGA nanoparticles prepared by nano-emulsion templating interact selectively with proteins involved in the transport through the blood-brain barrier.
    Monge M; Fornaguera C; Quero C; Dols-Perez A; Calderó G; Grijalvo S; García-Celma MJ; Rodríguez-Abreu C; Solans C
    Eur J Pharm Biopharm; 2020 Nov; 156():155-164. PubMed ID: 32927077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier.
    Tosi G; Bortot B; Ruozi B; Dolcetta D; Vandelli MA; Forni F; Severini GM
    Curr Med Chem; 2013; 20(17):2212-25. PubMed ID: 23458620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PLGA-PEG-ANG-2 Nanoparticles for Blood-Brain Barrier Crossing: Proof-of-Concept Study.
    Hoyos-Ceballos GP; Ruozi B; Ottonelli I; Da Ros F; Vandelli MA; Forni F; Daini E; Vilella A; Zoli M; Tosi G; Duskey JT; López-Osorio BL
    Pharmaceutics; 2020 Jan; 12(1):. PubMed ID: 31963430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-Carnitine-conjugated nanoparticles to promote permeation across blood-brain barrier and to target glioma cells for drug delivery via the novel organic cation/carnitine transporter OCTN2.
    Kou L; Hou Y; Yao Q; Guo W; Wang G; Wang M; Fu Q; He Z; Ganapathy V; Sun J
    Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):1605-1616. PubMed ID: 28974108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin- and folic acid-grafted poly(lactide-co-glycolide) nanoparticles.
    Kuo YC; Chen YC
    Int J Pharm; 2015 Feb; 479(1):138-49. PubMed ID: 25560309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier.
    Tosi G; Fano RA; Bondioli L; Badiali L; Benassi R; Rivasi F; Ruozi B; Forni F; Vandelli MA
    Nanomedicine (Lond); 2011 Apr; 6(3):423-36. PubMed ID: 21542682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of the degree of pegylation of poly(lactic-co-glycolic acid) nanoparticles in enhancing central nervous system delivery of loperamide.
    Kirby BP; Pabari R; Chen CN; Al Baharna M; Walsh J; Ramtoola Z
    J Pharm Pharmacol; 2013 Oct; 65(10):1473-81. PubMed ID: 24028614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polysorbate 80-coated PLGA nanoparticles improve the permeability of acetylpuerarin and enhance its brain-protective effects in rats.
    Sun D; Xue A; Zhang B; Lou H; Shi H; Zhang X
    J Pharm Pharmacol; 2015 Dec; 67(12):1650-62. PubMed ID: 26407669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PLGA Nanoparticle-Based Formulations to Cross the Blood-Brain Barrier for Drug Delivery: From R&D to cGMP.
    Zhi K; Raji B; Nookala AR; Khan MM; Nguyen XH; Sakshi S; Pourmotabbed T; Yallapu MM; Kochat H; Tadrous E; Pernell S; Kumar S
    Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33917577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly aspartic acid peptide-linked PLGA based nanoscale particles: potential for bone-targeting drug delivery applications.
    Jiang T; Yu X; Carbone EJ; Nelson C; Kan HM; Lo KW
    Int J Pharm; 2014 Nov; 475(1-2):547-57. PubMed ID: 25194353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal and intravenous administration of octa-arginine modified poly(lactic-co-glycolic acid) nanoparticles facilitates central nervous system delivery of loperamide.
    O'Donnell A; Moollan A; Baneham S; Ozgul M; Pabari RM; Cox D; Kirby BP; Ramtoola Z
    J Pharm Pharmacol; 2015 Apr; 67(4):525-36. PubMed ID: 25515568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crossing the blood-brain barrier with nanoparticles.
    Zhou Y; Peng Z; Seven ES; Leblanc RM
    J Control Release; 2018 Jan; 270():290-303. PubMed ID: 29269142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering PLGA nano-based systems through understanding the influence of nanoparticle properties and cell-penetrating peptides for cochlear drug delivery.
    Cai H; Liang Z; Huang W; Wen L; Chen G
    Int J Pharm; 2017 Oct; 532(1):55-65. PubMed ID: 28870763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploiting Bacterial Pathways for BBB Crossing with PLGA Nanoparticles Modified with a Mutated Form of Diphtheria Toxin (CRM197): In Vivo Experiments.
    Tosi G; Vilella A; Veratti P; Belletti D; Pederzoli F; Ruozi B; Vandelli MA; Zoli M; Forni F
    Mol Pharm; 2015 Oct; 12(10):3672-84. PubMed ID: 26312414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approach to treating spinal cord injury using PEG-TAT-modified, cyclosporine-A-loaded PLGA/polymeric liposomes.
    Gao SJ; Liu Y; Wang HJ; Ban DX; Cheng SZ; Ning GZ; Wang LL; Chang J; Feng SQ
    J Drug Target; 2017 Jan; 25(1):75-82. PubMed ID: 27250819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies.
    Han L; Jiang C
    Acta Pharm Sin B; 2021 Aug; 11(8):2306-2325. PubMed ID: 34522589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translocator protein ligand-PLGA conjugated nanoparticles for 5-fluorouracil delivery to glioma cancer cells.
    Laquintana V; Denora N; Lopalco A; Lopedota A; Cutrignelli A; Lasorsa FM; Agostino G; Franco M
    Mol Pharm; 2014 Mar; 11(3):859-71. PubMed ID: 24410438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro.
    Wang Y; Guo M; Lu Y; Ding LY; Ron WT; Liu YQ; Song FF; Yu SQ
    Nanotechnology; 2012 Dec; 23(49):495103. PubMed ID: 23149859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.